Small cell lung cancer (SCLC) remains one of the most challenging types of lung cancer with a highly metastatic potential and is traditionally resistant to standard chemotherapies in the relapsed ...
Combining immunotherapy with chemotherapy may improve survival in extensive-stage small cell lung cancer without increasing treatment-related toxicity. The study showed a median overall survival of 14 ...
The IMforte trial showed Zepzelca plus Tecentriq improved progression-free and overall survival in extensive-stage SCLC, suggesting a new first-line maintenance standard. DELPHI-304 demonstrated ...
Neoadjuvant immunotherapy plus chemotherapy shows a 35% pathological complete response rate and 49% major pathological response rate in LS-SCLC. Most patients achieved R0 surgical resection, with a 44 ...
TIGOS-LS, an open-label, randomized study of BMS-986489 vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer. This is an ASCO Meeting Abstract ...
The approval was supported by the randomized, double-blind, placebo-controlled phase 3 ADRIATIC study. Results showed durvalumab reduced the risk of death by 27% and disease progression or death by 24 ...
Ifinatamab deruxtecan targets B7-H3 and is a potential first-in-class antibody-drug conjugate for extensive-stage small cell lung cancer. The FDA's Breakthrough Therapy Designation aims to expedite ...
or on the link below. Small cell lung cancer (SCLC) represents the most aggressive and metastatic form of lung carcinoma, particularly in its extensive stage. Strongly associated with heavy smoking ...
The global downturn in tobacco use has led to a significant decline in the number of patients who are diagnosed with small-cell lung cancer (SCLC) on a yearly basis. But for those who do have SCLC, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results